Going mobile: Based on screening hit 1, a novel class of polyamine compounds, as represented by compound 8, were identified as potent and selective CXCR4 antagonists. CXCR4-targeted molecules, as demonstrated by the marketed AMD3100 and 8, are able to mobilize stem cells from bone marrow effectively and are expected to have broad utility in cell therapy and regenerative medicine.
